Total Knee Replacement Failure Calculator

1. Evidence Extraction & Model Rationale

• Primary baseline (any reoperation & any revision): piecewise-constant continuous hazards reconstructed from Chen et al. (2025), a Medicare-eligible institutional registry of 11,717 patients / 15,282 primary TKAs with 15-year follow-up. Survivorship free from any reoperation: S(2) = 96 %, S(5) = 95 %, S(10) = 93 %, S(15) = 90 %. Survivorship free from any revision: S(2) = 99 %, S(5) = 98 %, S(10) = 97 %, S(15) = 96 %.
• Hazard decomposition: total reoperation hazard is decomposed into revision (h_rev) and nonrevision reoperation (h_nrr = h_total − h_rev) within each interval, enabling separate covariate modulation (covariates apply to revision only).
• NRR front-loading: Zmistowski et al. (2011) report median NRR at 74.5 days (range 1–3,058 days). The 2-year NRR cumulative probability is redistributed so 84 % occurs in year 0–1 and 16 % in year 1–2, preserving the 2-year burden.
• No MA correction: Chen et al. use an institutional registry that captures events after TM-to-MA switching (16 % of reoperations and 22 % of revisions occurred post-switch). No additional ascertainment correction is needed.
• Conservative design: protective effects (female sex HR 0.82, older age HR 0.27, inflammatory arthritis HR 0.79, hypertension HR 0.96) are suppressed and set to neutral for conservatism. Covariate HRs are applied to revision hazard only.

2. Model Coefficients

Combined revision HR multiplier is capped at 3.0 (log cap ln(3)) to prevent implausible extremes. Covariate effects are applied to revision hazard only; NRR covariate effects were not quantified in the source PDFs.

3. Statistical Method

A discrete-time competing-risk recursion (1-year steps, Beyersmann et al. formulation) calculates the Cumulative Incidence Function (CIF) for any reoperation:

• Reoperation hazard (h_R): h_R(k) = h_rev(k) × revMult + h_nrr(k). Revision hazard is piecewise-constant per Chen intervals with covariate modulation; NRR hazard is front-loaded in years 0–1 per Zmistowski timing, then piecewise-constant thereafter.
• Death hazard (μ_D): derived from US Life Tables 2023 via μ = −ln(1 − q_x).
• CIF increment: CIF_R(t+1) = CIF_R(t) + S(t) × [1 − exp(−(h_R + μ_D))] × h_R / (h_R + μ_D).
• Overall survival: S(t+1) = S(t) × exp(−(h_R + μ_D)).
• Age input: continuous integer, used directly as starting age for mortality lookup and recursion length (to age 100).
• Extrapolation (> 15 years): hold Chen 10–15 interval hazards constant. For patients with surgery age < 65, years 15–24 use an elevated revision hazard (0.01223/yr) derived from Evans et al. 15-to-25-year registry survivorship decline (93.0 % → 82.3 %); after year 25, revert to the Chen 10–15 revision hazard.
• Terminal age: recursion runs to age 100.

4. Plausibility Checks

• Age 65 reference (Female, no risk factors): remaining-lifetime CIF ≈ 10 %. The baseline reproduces Chen 15-year survivorship (90 %) by construction; the lifetime extension adds ~0–1 pp from post-15-year tail hazard attenuated by competing mortality.
• Chen revision consistency: 5-year revision risk 2 % matches Curtin et al. Medicare 5-year incidence (2.0 %).
• Age 55 reference: remaining-lifetime CIF ≈ 19 %, reflecting more years at risk.
• Age 45 reference: remaining-lifetime CIF ≈ 35 %, combining elevated revision HR (2.13×) and Evans tail constraint.
• Older patients (age 75+) have lower CIF (≈ 7 %) due to competing mortality absorbing at-risk time.

These figures represent the remaining-lifetime probability, not a fixed-horizon rate.

5. Limitations

• Any-reoperation baseline is from a single high-volume center Medicare-eligible registry; generalizability to younger patients and broader practice settings is uncertain.
• The Chen PDF does not enumerate reoperation types; mapping “any reoperation” to revision + NRR relies on internal calibration to both endpoints rather than procedure-level linkage.
• Covariate effects (Dy) are time-to-revision HRs applied to revision hazard only; NRR covariate effects are not quantified.
• Non-US registry survivorship (Evans) constrains the 15–25 year revision tail for < 65-year-olds only, with transportability and implant-vintage limitations.
• HbA1c-specific effects (Adams) are 1-year ORs and are not extrapolated indefinitely.
• The model produces a population-level statistical estimate, not an individualized surgical prediction.

6. Bibliography

1. Chen AF, et al. Long-term survivorship of primary total knee arthroplasty in a large institutional registry: impact of Medicare Advantage transition on outcome ascertainment. 2025.
2. Dy CJ, et al. Risk factors for revision within 10 years of total knee arthroplasty. Clin Orthop Relat Res. 2014 Apr.
3. Zmistowski B, Restrepo C, Kahl LK, Parvizi J, Sharkey PF. Incidence and reasons for nonrevision reoperation after total knee arthroplasty. Clin Orthop Relat Res. 2011 Jan;469(1):138-145.
4. Adams AL, Paxton EW, Wang JQ, et al. Surgical outcomes of total knee replacement according to diabetes status and glycemic control, 2001-2009. J Bone Joint Surg Am. 2013;95(6):481-487.
5. Evans JT, et al. How long does a knee replacement last? A systematic review and meta-analysis of case series and national registry reports. Lancet. 2019;393:655-663.
6. Curtin BM, Bozic KJ, Englesbe MJ. Revision after total knee arthroplasty and total hip arthroplasty in Medicare patients. J Arthroplasty. 2012;27(8):1480-1486.
7. National Center for Health Statistics. United States Life Tables, 2023. National Vital Statistics Reports.
8. Beyersmann J, et al. Competing Risks and Multistate Models with R. Springer, 2012.